This Review summarizes the available data about combination immunotherapies in T1DM, particularly addressing their clinical importance
You get access to a licensed provider review, prescription if approved, and home delivery
1 Recommended Topics Recommended Topics
Several factors explain why Lilly has become the biggest winner : Record GLP-1 Sales: Mounjaro and ZepBound Source EvaluatePharma Lillys GLP-1 portfolio is led by Mounjaro (tirzepatide) and ZepBound (tirzepatide) , both based on the dual GLP-1/GIP agonist tirzepatide but marketed separately for diabetes and obesity
Some drugs have been proposed to accelerate -cell loss (e.g., glibenclamide and glyburide) [23], while other drugs such as peroxisome proliferator-activated receptor-gamma (PPAR) agonists, GLP-1 receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, glycogen synthase kinase 3 (GSK3) inhibitors, or G protein-coupled receptor 40 (GPR40) agonists have been suggested to protect -cell function [16]
